We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Dr. Wenyuan Shi is currently the Chief Executive Officer & Chief Science Officer of the Forsyth Institute, a Harvard affiliated research institute. Prior to this position, Dr. Shi is the chairman and professor of Oral Biology at UCLA School of Dentistry as well as the Professor of Microbiology, Immunology and Molecular Genetics at UCLA School of Medicine. Dr. Shi has been leading multiple NIH grants to use multidisciplinary approaches to study oral microbiome with a specific focus on microbial biofilm, inter-species interaction and signal transduction. In addition, Dr. Shi’s laboratory is actively involved in the development of next generation of diagnostic and therapeutic tools against oral microbial infections, including instant chairside detection of oral pathogens and peptide based targeted antimicrobial therapeutics. These translational research efforts have resulted in novel technologies that are licensed and developed by major pharmaceutical, dental and biotech companies. Dr. Shi is also the founding scientist, former chief scientific officer and chairman of the scientific advisory board of C3J Therapeutics Inc. (www.c3-jian.com).
Dr. Shi obtained his BS degree from Fudan University (Shanghai) in 1984, acquired his Ph.D degree from University of Wisconsin-Madison in 1991 and fulfilled his postdoctoral training at University of California-Berkeley during 1992-1995. He is co-author and co-inventor of over 220 scientific articles and 40 patents and patent applications.
This speaker's sessions: